Combination chemotherapy with nitrogen mustard, vincristine, procarbazine, and prednisone in lymphosarcoma and reticulum cell sarcoma.
TLDR
This study evaluates the use of a combination of 4 drugs—nitrogen mustard, vincristine, procarbazine, and prednisone—in patients with generalized lymphosarcoma and 8 patients with reticulum cell sarcoma to produce remissions of substantial duration in patients with LSA and RCS.Abstract:
This study evaluates the use of a combination of 4 drugs—nitrogen mustard, vincristine, procarbazine, and prednisone—in 15 patients with generalized lymphosarcoma (LSA) and 8 patients with reticulum cell sarcoma (RCS). Of the 15 patients with LSA, there were 7 complete remissions (CR) and 5 partial remissions (PR). Among the 8 RCS patients, 3 achieved CR and 2 achieved PR. The mean duration of unmaintained complete remission calculated from therapy completion was 11.7+ mos. (0–25+) for LSA patients and 32+ mos. (23–37+) for RCS patients. Mean survival from the onset of therapy was 30.6+ mos. (18–45+) for the LSA patients achieving CR with 5 of 7 patients still surviving and 2 patients still free of disease. For RCS patients, survival was 30+, 42+, and 42+ mos. for the 3 patients achieving CR, with all 3 still free of disease. Moderate myelosuppression was produced. This combination of agents produces remissions of substantial duration in patients with LSA and RCS.read more
Citations
More filters
Journal ArticleDOI
Advanced diffuse histiocytic lymphoma, a potentially curable disease.
Vincent T. DeVita,George P. Canellos,Bruce A. Chabner,Philip S. Schein,SusanP. Hubbard,R. C. Young +5 more
TL;DR: Twenty-seven patients with advanced diffuse histiocytic lymphoma (reticulum-cell sarcoma) were treated with combination chemotherapy utilising nitrogen mustard, procarbazine, vincristine, and prednisone and only one has had a recurrence of tumour.
Journal ArticleDOI
Diffuse aggressive lymphomas: increased survival after alternating flexible sequences of proMACE and MOPP chemotherapy.
Richard I. Fisher,Vincent T. DeVita,Susan M. Hubbard,Dan L. Longo,Robert Wesley,Bruce A. Chabner,Robert C. Young +6 more
TL;DR: ProMACE-MOPP chemotherapy represents a substantial improvement in treating patients with diffuse aggressive lymphomas and is predicted to exceed 4 years with 65% of patients alive at 4 years.
Journal ArticleDOI
Advanced Lymphosarcoma: Intensive Cyclical Combination Chemotherapy with Cyclophosphamide, Vincristine, and Prednisone
TL;DR: In this article, 35 patients with advanced lymphosarcoma (32 without previous therapy) were treated with intensive 5-day courses of cyclophosphamide and prednisone, with vincristine given on the f
Journal ArticleDOI
The contribution of cytotoxic chemotherapy to 5-year survival in adult malignancies
TL;DR: It is clear that cytotoxic chemotherapy only makes a minor contribution to cancer survival in adults, and a rigorous evaluation of the cost-effectiveness and impact on quality of life is urgently required.
Journal Article
The chemotherapy of lymphomas: looking back, moving forward--the Richard and Hinda Rosenthal Foundation award lecture.
TL;DR: The lessons learned by looking back at the treatment of lymphomas are applicable to other common malignancies of adults and should not deter the clinical investigators from defining their ultimate role in treatment in the most expeditious way.
References
More filters
Journal ArticleDOI
Extensive histological and cytological survey of patients with acute leukaemia in "complete remission".
Georges Mathé,Schwarzenberg L,A. M. Mery,A. Cattan,Schneider M,Jean-Louis Amiel,J. R. Schlumberger,J. Poisson,G. Wajcner +8 more
TL;DR: A much higher proportion of volunteers showed an antibody response after live than after inactivated vaccine, and except perhaps in volunteers with antibody there was little difference in efficacy of administration by nasal drops or spray.
Journal Article
Management of patients with malignant lymphoma: a comparative study with cyclophosphamide and vinca alkaloids.
Paul P. Carbone,Charles L. Spurr,Marvin A. Schneiderman,Scotto J,James F. Holland,Bruce I. Shnider +5 more
Journal ArticleDOI
The Persistence of Extramedullary Leukemic Infiltrates during Bone Marrow Remission of Acute Leukemia
TL;DR: Findings indicate that leukemic cells are not completely eradicated by current chemotherapy even in patients in whom no leukedmic cells can be identified in the bone marrow.
Journal ArticleDOI
Combination chemotherapy in lymphosarcoma and reticulum cell sarcoma.
Barth Hoogstraten,Albert H. Owens,Raymond E. Lenhard,Oliver J. Glidewell,Louis A. Leone,Kenneth B. Olson,John B. Harley,Stuart R. Townsend,Sherwood P. Miller,Charles L. Spurr +9 more
TL;DR: Remissions as measured by decrease in tumor size were associated with improvement in hemoglobin, performance, food intake, weight and fever, and the study provides impetus for further trial with other drug combinations and schedules.
Journal ArticleDOI
A Methylhydrazine Derivative in Hodgkin's Disease and Other Malignant Neoplasms: Therapeutic and Toxic Effects Studied in 51 Patients
Kurt W. Brunner,Charles W. Young +1 more
TL;DR: Methylhydrazine derivatives form a new class of synthetic cytotoxic compounds that possess antineoplastic activity in animal tumor systems and in patients with malignant lymphoma.